Inhibikase (IKT) Director Dennis Berman Exercises Options

What Happened
Dennis N. Berman, a director of Inhibikase Therapeutics (IKT), exercised stock options on July 30, 2026 to acquire 21,854 shares at an exercise price of $1.26 per share, for a cash outlay of $27,536. The Form 4 also reports a related derivative conversion for 21,854 shares at $0.00 (this represents conversion of the option into common stock, not an open‑market sale). The filing notes the options were fully vested and exercisable.

Key Details

• Transaction date: 2026-07-30 (filed 2026-07-31) — filing appears within the normal Form 4 reporting window.
• Exercise: 21,854 shares acquired at $1.26 each; total cash paid $27,536.
• Reported derivative conversion: 21,854 shares at $0.00 (reflects conversion of the option into shares).
• Footnote: F1 — options are fully vested and exercisable.
• Shares owned after transaction: not specified in the provided excerpt.
• Transaction code M = option exercise/derivative conversion.

Context
This was an exercise of vested options (a purchase of shares via option exercise), not a sale; no immediate open‑market sale of the acquired shares is reported in the provided filing. Option exercises can reflect routine option realization by insiders; purchases (including exercises) are often considered more informative than sales, but they do not by themselves indicate the insider’s view of future performance.